• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Cspc Pharmaceutical Group Ltd ADR (OP: CSPCY )

    3.060 -0.060 (-1.92%)
    Streaming Delayed Price Updated: 3:51 PM EDT, Aug 20, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Cspc Pharmaceutical Group Ltd ADR

    BenQ Hospital Files For IPO As Business Looks Stable, But With Few Growth Spots
    Key Takeaways: BenQ Hospital has filed to list in Hong Kong, reporting its revenue rose 15% last year to 2.69 billion yuan  China’s largest private hospital operator will use its IPO funds to expand... 
    Via Benzinga
    Topics Initial Public Offering
    Exposures Securities Market
    Investors Take Note as Corbus Pharma Releases Data for ADC Tumor Candidate
    Via Get News
    Exposures Product Safety
    Investors Take Note as Corbus Pharma Releases Data for ADC Tumor Candidate
    --News Direct-- 
    Via News Direct
    Investors Take Note as Corbus Pharma Releases Data for ADC Tumor Candidate
    New York, Jan. 29, 2024 - (Plato Data) -- Corbus Pharmaceuticals (NASDAQ:CRBP) jumped on Friday after announcing positive data from a small group of cancer patients who received its antibody-drug... 
    Via TheNewswire.com
    Exposures Product Safety
    China's First mRNA Vaccine: Drugmaker CSPC Wins China's Approval For COVID-19 Vaccine
    Chinese health authorities approved CSPC Pharmaceuticals Group Ltd's (OTC: CSPCY) messenger RNA (mRNA) COVID-19 vaccine for emergency use authorization. 
    Via Benzinga
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.